PM060184 es el Cuarto Farmaco del Pipeline de PharmaMar y esta Pendiente de Iniciar la Fase II en Cáncer de Mama y en ColoRectal .... Pharma Mar USA , Inc esta llevando a cabo tambien una Fase I del PM060184 en Combinación con Gemcitabine ( Gemzar Eli Lilly ).

ClinicalTrials Identifier : NCT02533674
Updated : 2015_08_26 .

Descriptive Information :

Brief title Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM060184 in Combination With Gemcitabine in Selected Patients With Advanced Solid Tumors .

Administrative Data :

Organization name : PharmaMar
Organization study : ID PM60184-A-003-14
Secondary : ID PM60184-A-003-14 (Pharma Mar USA, Inc.)
Secondary : ID 2014-002943-16 (EudraCT Number)
Sponsor : PharmaMar
Health Authority United States : Food and Drug Administration
Health Authority Spain : Agencia Española de Medicamentos y Productos Sanitarios
Health Authority Spain : Ethics Committee
Health Authority United States : Institutional Review Board .

...